Cargando…

Increase of angiotensin II type 1 receptor auto-antibodies in Huntington’s disease

BACKGROUND: In the recent years, a role of the immune system in Huntington’s disease (HD) is increasingly recognized. Here we investigate the presence of T cell activating auto-antibodies against angiotensin II type 1 receptors (AT1R) in all stages of the disease as compared to healthy controls and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, De-Hyung, Heidecke, Harald, Schröder, Alexandra, Paul, Friedemann, Wachter, Rolf, Hoffmann, Rainer, Ellrichmann, Gisa, Dragun, Duska, Waschbisch, Anne, Stegbauer, Johannes, Klotz, Peter, Gold, Ralf, Dechend, Ralf, Müller, Dominik N, Saft, Carsten, Linker, Ralf A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246494/ https://www.ncbi.nlm.nih.gov/pubmed/25398321 http://dx.doi.org/10.1186/1750-1326-9-49

Ejemplares similares

The Role of the Immune System in Huntington's Disease
por: Ellrichmann, Gisa, et al.
Publicado: (2013)

Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
por: Ellrichmann, Gisa, et al.
Publicado: (2011)

Predictive and Prognostic Value of sPRR in Patients with Primary Epithelial Ovarian Cancer
por: Kreienbring, Katrin, et al.
Publicado: (2016)

Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation
por: Ellrichmann, Gisa, et al.
Publicado: (2012)

Positive effect of immunomodulatory therapies on disease progression in Huntington’s disease? Data from a real-world cohort
por: Achenbach, Jannis, et al.
Publicado: (2022)

Error Processing in Huntington's Disease
por: Beste, Christian, et al.
Publicado: (2006)

Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders
por: Ellrichmann, Gisa, et al.
Publicado: (2018)

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
por: Schneider-Gold, Christiane, et al.
Publicado: (2017)

Molecular Effects of Auto-Antibodies on Angiotensin II Type 1 Receptor Signaling and Cell Proliferation
por: Philippe, Aurélie, et al.
Publicado: (2022)

Time Processing in Huntington's Disease: A Group-Control Study
por: Beste, Christian, et al.
Publicado: (2007)

Insight into Metabolic (1)H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions
por: Schneider, Ruth, et al.
Publicado: (2017)

Author Correction: Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2019)

Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2017)

The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
por: Hammer, Anna, et al.
Publicado: (2018)

Vascular pathology in multiple sclerosis: mind boosting or myth busting?
por: Waschbisch, Anne, et al.
Publicado: (2011)

Brainstem Encephalitis With Low-Titer Acetylcholine Receptor Antibodies Mimicking Myasthenia Gravis
por: Ayzenberg, Ilya, et al.
Publicado: (2019)

Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients
por: Günther, Jeannine, et al.
Publicado: (2014)

Metabolic profiles by (1)H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)
por: Schneider, Ruth, et al.
Publicado: (2017)

Kidney re-transplantation in a child across the barrier of persisting angiotensin II type I receptor antibodies
por: Gold, Annika, et al.
Publicado: (2020)

Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis
por: Waschbisch, Anne, et al.
Publicado: (2011)

Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis
por: Kill, Angela, et al.
Publicado: (2014)

Relaxin Does Not Improve Angiotensin II-Induced Target-Organ Damage
por: Haase, Nadine, et al.
Publicado: (2014)

Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters
por: Lee, De-Hyung, et al.
Publicado: (2012)

Immunomodulatory and anti-oxidative effect of the direct TRPV1 receptor agonist capsaicin on Schwann cells
por: Grüter, Thomas, et al.
Publicado: (2020)

Receptor autoantibodies: Associations with cardiac markers, histology, and function in human non‐ischaemic heart failure
por: Zweck, Elric, et al.
Publicado: (2023)

Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab
por: Lee, De-Hyung, et al.
Publicado: (2013)

Evidences for Mutant Huntingtin Inducing Musculoskeletal and Brain Growth Impairments via Disturbing Testosterone Biosynthesis in Male Huntington Disease Animals
por: Yu-Taeger, Libo, et al.
Publicado: (2022)

Diagnostik, Therapie und die Bedeutung der Lebensqualität von Patienten mit chronischem Koronarsyndrom: Ergebnisse der hausärztlichen Versorgungsstudie ALTHEA
por: Dechend, Ralf
Publicado: (2022)

Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome in seven patients with sarcoidosis: a critical discussion of treatment and prognosis
por: Dohrn, Maike F., et al.
Publicado: (2021)

Demyelinating disease and anti-N-methyl-D-aspartate receptor immunoglobulin G antibodies: a case report
por: Waschbisch, Anne, et al.
Publicado: (2014)

Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report
por: Lee, De-Hyung, et al.
Publicado: (2014)

IgG stimulated β2 adrenergic receptor activation is attenuated in patients with ME/CFS
por: Hartwig, Jelka, et al.
Publicado: (2020)

Novel variants in a patient with late-onset hyperprolinemia type II: diagnostic key for status epilepticus and lactic acidosis
por: Motte, Jeremias, et al.
Publicado: (2019)

Role of Nuclear Factor (Erythroid-Derived 2)-Like 2 Signaling for Effects of Fumaric Acid Esters on Dendritic Cells
por: Hammer, Anna, et al.
Publicado: (2017)

Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study
por: Stasiolek, Mariusz, et al.
Publicado: (2015)

High cut-off dialysis mitigates pro-calcific effects of plasma on vascular progenitor cells
por: Schaub, Theres, et al.
Publicado: (2021)

Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits
por: Thöne, Jan, et al.
Publicado: (2013)

Symptomatic treatment options for Huntington’s disease (guidelines of the German Neurological Society)
por: Saft, Carsten, et al.
Publicado: (2023)

Does arterial hypertension influence the onset of Huntington's disease?
por: Valcárcel-Ocete, Leire, et al.
Publicado: (2018)

Visual Search as a Tool for a Quick and Reliable Assessment of Cognitive Functions in Patients with Multiple Sclerosis
por: Utz, Kathrin S., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ca6q9c2vc3o2btljvr3p8rua0f